Damora Therapeutics, Inc. (DMRA) shareholders
Close on Nov 17, 2026Market cap $1.39BP/E 5.7Yield 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Peter Evan Harwin Joint filing with Fairmount Funds Management LLC (19.99%), Tomas Kiselak (19.99%) and 2 more | 8,713,000 | 19.99% | 13D (active) amendment | Feb 9, 2026 |
| Avoro Capital Advisors LLC Joint filing with Behzad Aghazadeh (6.27%) | 3,783,000 | 6.27% | 13G (passive) | Mar 31, 2026 |
| VHCP Co-Investment Holdings III, LLC Joint filing with Venrock Healthcare Capital Partners III, L.P. (6.00%), Venrock Healthcare Capital Partners EG, L.P. (6.00%) and 4 more | 3,603,595 | 6.00% | 13G (passive) | Feb 9, 2026 |
| BlackRock, Inc. | 3,143,576 | 5.10% | 13G (passive) | Jun 30, 2026 |
| Otto Erik | 2,060,000 | 7.60% | 13G (passive) amendment | Dec 31, 2023 |
| Fairmount Healthcare Fund II L.P. Joint filing with Fairmount Funds Management LLC (19.99%), Fairmount Healthcare Co-Invest V L.P. (19.99%) and 2 more | 397,000 | 19.99% | 13D (active) | Nov 10, 2025 |
| Neil Shahrestani Joint filing with Ikarian Capital, LLC (21.50%) | 285,710 | 21.50% | 13G (passive) | Nov 30, 2025 |
| Abigail P. Johnson Joint filing with FMR LLC (15.00%) | 238,878 | 15.00% | 13G (passive) | Nov 28, 2025 |
| Jain Global LLC Joint filing with Jain Holdings LLC (7.50%), Robert Jain (7.50%) | 120,566 | 7.50% | 13G (passive) | Dec 31, 2025 |
| Point72 Asset Management, L.P. Joint filing with Point72 Capital Advisors, Inc. (6.30%), Steven A. Cohen (6.30%) | 100,001 | 6.30% | 13G (passive) | Nov 12, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DMRA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 9,232,979 | 14.96% | $240.15M | +187,498 | 0.01% |
| Fairmount Funds Management LLC | 8,713,000 | 14.11% | $226.63M | – | 14.98% |
| Avoro Capital Advisors LLC | 3,783,000 | 6.13% | $98.40M | – | 0.88% |
| VR Adviser, LLC | 3,603,595 | 5.84% | $93.73M | – | 2.84% |
| BlackRock, Inc. | 3,162,068 | 5.12% | $82.25M | +2,939,631 | 0.00% |
| Fcpm Iii Services B.V. | 2,441,000 | 3.95% | $63.49M | – | 8.46% |
| Ra Capital Management, L.P. | 2,399,702 | 3.89% | $62.42M | +392 | 0.54% |
| Viking Global Investors LP | 2,311,082 | 3.74% | $60.11M | – | 0.17% |
| Jupiter Topco LLC | 2,282,804 | 3.70% | $59.28M | New | 0.02% |
| JPMorgan Chase & Co | 2,058,933 | 3.34% | $49.85M | New | 0.00% |
| Remedium Capital Partners, LLC | 2,045,473 | 3.31% | $53.20M | – | 11.78% |
| Commodore Capital LP | 1,939,000 | 3.14% | $50.43M | – | 3.00% |
| Braidwell LP | 1,620,377 | 2.62% | $42.15M | +725,531 | 1.56% |
| Bellevue Group AG | 1,618,846 | 2.62% | $42.11M | −679,154 | 0.89% |
| State Street Corp | 1,545,500 | 2.50% | $40.20M | +1,361,578 | 0.00% |
| a16z Capital Management, L.L.C. | 1,236,157 | 2.00% | $32.15M | – | 0.23% |
| Balyasny Asset Management L.P. | 1,229,127 | 1.99% | $31.97M | −218,873 | 0.04% |
| Perceptive Advisors LLC | 1,223,000 | 1.98% | $31.81M | – | 0.48% |
| Wellington Management Group Llp | 1,058,000 | 1.71% | $27.52M | – | 0.00% |
| Blackstone Inc. | 1,002,971 | 1.62% | $26.09M | +499,449 | 0.08% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 101 | 65M | 100.0% | 50 / 28 | 9 / 13 | 15M | 4M |
| Q1 2026 | 65 | 56M | 90.9% | 51 / 13 | 0 / 3 | 55M | 0M |
| Q4 2025 | 18 | 1M | 1.8% | 12 / 3 | 3 / 6 | 1M | 0M |
| Q3 2025 | 12 | 0M | 0.3% | 4 / 3 | 3 / 1 | 0M | 0M |
| Q2 2025 | 9 | 0M | 0.2% | 0 / 3 | 4 / 2 | 0M | 0M |
| Q1 2025 | 11 | 0M | 0.2% | 3 / 2 | 1 / 2 | 0M | 0M |
| Q4 2024 | 10 | 0M | 0.2% | 3 / 2 | 2 / 3 | 0M | 0M |
| Q3 2024 | 10 | 0M | 0.2% | 10 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
81 funds held DMRA in Q2 2026, 25% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of DMRA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 1,828,909 | 2.96% | $45.50M | 0.05% | May 31, 2026 |
| iShares Russell 2000 ETF | 1,355,386 | 2.20% | $35.25M | 0.04% | Jun 30, 2026 |
| JPMorgan Small Cap Growth Fund | 741,346 | 1.20% | $19.28M | 0.74% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 714,931 | 1.16% | $18.60M | 0.17% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 535,388 | 0.87% | $13.32M | 0.05% | May 31, 2026 |
| Select Health Care Portfolio | 500,000 | 0.81% | $12.44M | 0.22% | May 31, 2026 |
| Select Biotechnology Portfolio | 454,559 | 0.74% | $11.31M | 0.21% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 452,806 | 0.73% | $11.27M | 0.05% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 339,291 | 0.55% | $8.82M | 0.06% | Jun 30, 2026 |
| JPMorgan Small Cap Blend Fund | 238,497 | 0.39% | $6.20M | 0.37% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 212,658 | 0.34% | $5.53M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 154,350 | 0.25% | $4.01M | 0.03% | Jun 30, 2026 |
| VIP Health Care Portfolio | 118,000 | 0.19% | $3.07M | 0.27% | Jun 30, 2026 |
| VIP Contrafund Portfolio | 105,500 | 0.17% | $2.74M | 0.01% | Jun 30, 2026 |
| Master Small Cap Index Series | 95,134 | 0.15% | $2.47M | 0.04% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jennifer Jarrett | Director, President and CEO | 512,500 | 0.83% | Sep 28, 2026 |
| Hans T. Schambye | Chief Executive Officer, Director | 4,682 | 0.01% | Jan 6, 2026 |
| Garrett Winslow | General Counsel | 2,289 | 0.00% | Jul 7, 2026 |
| Brian Burkavage | SVP, Finance | – | – | May 8, 2026 |
| Sherwin Sattarzadeh | Chief Operating Officer | 190,376 | 0.31% | Jan 26, 2026 |
| L. Becker Hewes | Chief Medical Officer | 264,629 | 0.43% | Jan 7, 2026 |
| Lori Firmani | Chief Financial Officer | 931 | 0.00% | Jan 6, 2026 |
| Matthew Kronmiller | EVP Strategy and CBO | – | – | Jan 7, 2025 |
| Andrew Cheng | Director | – | – | Aug 13, 2026 |
| Healthcare Fund II L.P. Fairmount | Director, 10% owner | 8,713,000 | 14.11% | Mar 25, 2026 |
| Cameron Turtle | Director | – | – | Mar 25, 2026 |
| Christopher W. Cain | Director | – | – | Mar 25, 2026 |
| Peter Evan Harwin | Director, 10% owner | – | – | Mar 25, 2026 |
| Funds Management LLC Fairmount | Director, 10% owner | – | – | Mar 25, 2026 |
| Julianne Bruno | Director | 137,032 | 0.22% | Mar 25, 2026 |
| Healthcare Co-Invest V. L.P. Fairmount | Director, 10% owner | – | – | Mar 25, 2026 |
| Michael Landsittel | Director | – | – | Mar 25, 2026 |
| David Shapiro | Director | – | – | Jun 20, 2025 |
| Jayson Donald Alexander Dallas | Director | – | – | Jun 20, 2025 |
| Amit Munshi | Director | 4,793 | 0.01% | Jun 20, 2025 |
| Anne Prener | Director | – | – | Jun 20, 2025 |
| Carl Goldfischer | Director | 1,049,055 | 1.70% | Jun 20, 2025 |
| Amy B. Wechsler | Director | – | – | Jun 20, 2025 |
| Tomas Kiselak | 10% owner | – | – | Mar 25, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jennifer Jarrett Director, President and CEO | Sep 25, 2026 | Buy | +12,500 | $20.23 | $252.88K | 512,500 |
| Garrett Winslow General Counsel | Jul 6, 2026 | Sale | −245 | $29.98 | $7.35K | 2,289 |
| Garrett Winslow General Counsel | Jul 3, 2026 | Option exercise | +680 | – | – | 2,534 |
| Jennifer Jarrett See Remarks, Director | Mar 30, 2026 | Award | +500,000 | – | – | 500,000 |
| Julianne Bruno Director | Feb 9, 2026 | Option exercise | +129,000 | – | – | 137,032 |
| Healthcare Fund II L.P. Fairmount 10% owner | Feb 9, 2026 | Option exercise | +2,904,000 | – | – | 2,904,000 |
| Healthcare Fund II L.P. Fairmount 10% owner | Feb 9, 2026 | Option exercise | +5,809,000 | – | – | 5,809,000 |
| Sherwin Sattarzadeh Chief Operating Officer | Jan 5, 2026 | Award | +190,376 | – | – | 190,376 |
| L. Becker Hewes Chief Medical Officer | Jan 5, 2026 | Award | +264,629 | – | – | 264,629 |
| Hans T. Schambye Chief Executive Officer, Director | Jan 2, 2026 | Sale | −700 | $21.38 | $14.97K | 4,682 |
| Hans T. Schambye Chief Executive Officer, Director | Jan 2, 2026 | Option exercise | +1,360 | – | – | 5,382 |
| Lori Firmani Chief Financial Officer | Jan 2, 2026 | Sale | −135 | $21.41 | $2.89K | 931 |
| Lori Firmani Chief Financial Officer | Jan 2, 2026 | Option exercise | +374 | – | – | 1,066 |
| Garrett Winslow General Counsel | Jan 2, 2026 | Option exercise | +680 | – | – | 2,109 |
| Garrett Winslow General Counsel | Jan 2, 2026 | Sale | −255 | $21.38 | $5.45K | 1,854 |
| Hans T. Schambye Chief Executive Officer, Director | Jul 3, 2025 | Option exercise | +1,360 | – | – | 4,757 |
| Hans T. Schambye Chief Executive Officer, Director | Jul 3, 2025 | Sale | −735 | $3.38 | $2.48K | 4,022 |
| Garrett Winslow General Counsel | Jul 3, 2025 | Sale | −260 | $3.39 | $881 | 1,429 |
| Garrett Winslow General Counsel | Jul 3, 2025 | Option exercise | +680 | – | – | 1,689 |
| Lori Firmani Interim CFO | Jul 3, 2025 | Sale | −147 | $3.39 | $498 | 692 |
| Lori Firmani Interim CFO | Jul 3, 2025 | Option exercise | +374 | – | – | 839 |
| Hans T. Schambye Chief Executive Officer, Director | Jan 3, 2025 | Sale | −1,341 | $5.60 | $7.51K | 3,397 |
| Hans T. Schambye Chief Executive Officer, Director | Jan 3, 2025 | Option exercise | +2,640 | – | – | 4,738 |
| Garrett Winslow General Counsel | Jan 3, 2025 | Sale | −471 | $5.60 | $2.64K | 1,009 |
| Garrett Winslow General Counsel | Jan 3, 2025 | Option exercise | +1,320 | – | – | 1,480 |
| Lori Firmani Interim CFO | Jan 3, 2025 | Sale | −261 | $5.63 | $1.47K | 465 |
| Lori Firmani Interim CFO | Jan 3, 2025 | Option exercise | +726 | – | – | 726 |
| Advisors Israel II Ltd OrbiMed 10% owner | Aug 15, 2023 | Sale | −248,819 | $0.75 | $186.61K | 631,048 |
| Advisors Israel II Ltd OrbiMed 10% owner | Aug 15, 2023 | Sale | −38,327 | $0.75 | $28.75K | 97,204 |
| Advisors Israel II Ltd OrbiMed 10% owner | Aug 15, 2023 | Sale | −535,534 | $0.75 | $401.65K | 1,510,375 |
| Capital GP VII LLC OrbiMed 10% owner | Jul 31, 2023 | Sale | −153,078 | $3.00 | $459.23K | 2,105,909 |
| Capital GP VII LLC OrbiMed 10% owner | Jul 31, 2023 | Sale | −29,700 | $3.00 | $89.10K | 879,867 |
| Capital GP VII LLC OrbiMed 10% owner | Jul 31, 2023 | Sale | −26,622 | $3.00 | $79.87K | 135,531 |
| Capital GP VII LLC OrbiMed 10% owner | Jul 25, 2023 | Sale | −4,700 | $2.92 | $13.72K | 909,567 |
| Capital GP VII LLC OrbiMed 10% owner | Jul 25, 2023 | Sale | −7,800 | $2.92 | $22.78K | 162,153 |
| Capital GP VII LLC OrbiMed 10% owner | Jul 25, 2023 | Sale | −26,700 | $2.92 | $77.96K | 2,258,987 |
| Advisors Israel II Ltd OrbiMed 10% owner | Jul 13, 2023 | Sale | −52,800 | $2.40 | $126.72K | 914,267 |
| Advisors Israel II Ltd OrbiMed 10% owner | Jul 13, 2023 | Sale | −132,100 | $2.40 | $317.04K | 2,285,687 |
| Advisors Israel II Ltd OrbiMed 10% owner | Jul 13, 2023 | Sale | −9,800 | $2.40 | $23.52K | 169,953 |
| Advisors Llc Orbimed 10% owner | Apr 17, 2023 | Sale | −660 | $1.97 | $1.30K | 179,753 |
| Advisors Llc Orbimed 10% owner | Apr 17, 2023 | Sale | −8,878 | $1.97 | $17.49K | 2,417,787 |
| Advisors Llc Orbimed 10% owner | Apr 17, 2023 | Sale | −3,551 | $1.97 | $7.00K | 967,067 |
| Advisors Llc Orbimed 10% owner | Apr 14, 2023 | Sale | −28,110 | $1.86 | $52.28K | 2,426,665 |
| Advisors Llc Orbimed 10% owner | Apr 14, 2023 | Sale | −11,245 | $1.86 | $20.92K | 970,618 |
| Advisors Llc Orbimed 10% owner | Apr 14, 2023 | Sale | −2,091 | $1.86 | $3.89K | 180,413 |
| Advisors Llc Orbimed 10% owner | Apr 13, 2023 | Sale | −703 | $1.82 | $1.28K | 182,504 |
| Advisors Llc Orbimed 10% owner | Apr 13, 2023 | Sale | −3,784 | $1.82 | $6.89K | 981,863 |
| Advisors Llc Orbimed 10% owner | Apr 13, 2023 | Sale | −9,459 | $1.82 | $17.22K | 2,454,775 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 12, 2023 | Sale | −641 | $1.81 | $1.16K | 985,647 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 12, 2023 | Sale | −119 | $1.81 | $215 | 183,207 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 12, 2023 | Sale | −1,603 | $1.81 | $2.90K | 2,464,234 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 11, 2023 | Sale | −3,784 | $1.82 | $6.89K | 986,288 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 11, 2023 | Sale | −703 | $1.82 | $1.28K | 183,326 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 11, 2023 | Sale | −9,459 | $1.82 | $17.22K | 2,465,837 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 10, 2023 | Sale | −34,745 | $1.79 | $62.19K | 2,500,582 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 10, 2023 | Sale | −13,899 | $1.79 | $24.88K | 1,000,187 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 10, 2023 | Sale | −2,584 | $1.79 | $4.63K | 185,910 |
| Genesis GP LLC OrbiMed 10% owner | Apr 6, 2023 | Sale | −487 | $2.00 | $974 | 186,613 |
| Genesis GP LLC OrbiMed 10% owner | Apr 6, 2023 | Sale | −2,620 | $2.00 | $5.24K | 1,003,971 |
| Genesis GP LLC OrbiMed 10% owner | Apr 6, 2023 | Sale | −6,558 | $2.00 | $13.12K | 2,510,041 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 8 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Damora Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 151,705 shares on Sep 16, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Lori Firmani Officer | Aug 6, 2026 | 1,800 | $55.98K | Aug 5, 2026 | Option |
| Lori Firmani Officer | Jun 22, 2026 | 7,615 | $193.14K | Jun 22, 2026 | Option |
| The Biotech Growth Trust PLC Shareholder | Oct 2, 2023 | 57,312 | $41.27K | Oct 2, 2023 | Private Placement |
| OrbiMed Israel Partners II, L.P. Shareholder | Oct 2, 2023 | 244,527 | $176.06K | Oct 2, 2023 | Private placement |
| OrbiMed Private Investments VII, LP Shareholder | Oct 2, 2023 | 585,274 | $421.40K | Oct 2, 2023 | Private placement |
| OrbiMed Genesis Master Fund, L.P. Shareholder | Oct 2, 2023 | 37,675 | $27.13K | Oct 2, 2023 | Private placement |
| OrbiMed Private Investments VII, LP Shareholder | Aug 30, 2023 | 1,222,125 | $708.83K | Aug 30, 2023 | Private placement |
| OrbiMed Genesis Master Fund, L.P. Shareholder | Aug 30, 2023 | 78,659 | $45.62K | Aug 30, 2023 | Private placement |
| OrbiMed Israel Partners II, L.P. Shareholder | Aug 30, 2023 | 510,610 | $296.15K | Aug 30, 2023 | Private placement |
| The Biotech Growth Trust PLC Shareholder | Aug 30, 2023 | 119,679 | $69.41K | Aug 30, 2023 | Private Placement |
| OrbiMed Israel Partners II, L.P. Shareholder | Aug 21, 2023 | 631,048 | $389.36K | Aug 21, 2023 | Private placement |
| The Biotech Growth Trust PLC Shareholder | Aug 21, 2023 | 147,910 | $91.26K | Aug 21, 2023 | Private placement |
| OrbiMed Private Investments VII, LP Shareholder | Aug 21, 2023 | 1,510,375 | $931.90K | Aug 21, 2023 | Private placement |
| OrbiMed Genesis Master Fund, L.P. Shareholder | Aug 21, 2023 | 75,473 | $56.61K | Aug 15, 2023 | Private placement |
| OrbiMed Genesis Master Fund, L.P. Shareholder | Aug 21, 2023 | 97,204 | $59.98K | Aug 21, 2023 | Private placement |
See a number that looks wrong?